IXth International Pulmonary Hypertension Conference: Scientific Sessions

第九届国际肺动脉高压会议：科学会议

• 批准号: 8007167
• 负责人: Ivan M Robbins
• 金额: $ 1万
• 依托单位: PULMONARY HYPERTENSION ASSOCIATION
• 依托单位国家: 美国
• 财政年份: 2010
• 资助国家: 美国
• 起止时间: 2010-06-07 至 2011-06-06
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8007167
• 关键词: Address; Blood Vessels; California; Cardiovascular system; Caregivers; Clinical; Collaborations; Disease; Education; FDA approved; Fostering; Funding; Future; Growth Factor; Health Professional; Individual; Inflammation; Inflammatory; International; Life; Lung; Medical; Medical Research; National Heart, Lung, and Blood Institute; Pathway interactions; Patients; Personal Communication; Pulmonary Heart Disease; Pulmonary Hypertension; Quality of life; Research; Research Personnel; Scientist; Services; Translational Research; United States; Update; abstracting; interest; meetings; posters; profession allied to medicine; programs; public health relevance; pulmonary arterial hypertension; symposium

DESCRIPTION (provided by applicant): The Pulmonary Hypertension Association (PHA) was incorporated in 1990 with an approximate membership of 100 individuals and has grown to its current membership of 10,000 that includes patients, caregivers, clinicians, research scientists, and allied health professionals. It supports a wide range of services and educational and research programs to benefit its large and diverse membership. One of the major activities supported by PHA is a biennial International Pulmonary Hypertension Conference. The meeting is unique in that it brings together medical professionals and researchers with the patients. The 9th International Conference will be held in Garden Grove, California on June 24-27, 2010. The Conference will begin with the Scientific Sessions for researchers and health professionals entitled Inflammation and Growth Factors in Pulmonary Arterial Hypertension (PAH). The Scientific Sessions begins on the evening of June 24 and continues throughout the day on June 25. Specific objectives of the Scientific Sessions are: 1) provide a forum for presentation of pivotal research results in PAH-related topics; 2) encourage open exchange of ideas regarding new directions for collaborative research in PAH; 3) highlight research accomplishments of junior investigators in the field to promote a life-long commitment to PAH; and 4) promote collaboration between basic and clinical researchers to stimulate more translational research. The Scientific Sessions will include an opening session to discuss the Cardiovascular Medical Research and Education Fund (CMREF) program and an update on the NHLBI Pulmonary Vascular SCCOR program, an all day session with five keynote scientists discussing various aspects of inflammation, growth factors and cardiopulmonary disease, four abstract presentations from the poster session, and a poster viewing session of an anticipated 75 posters. The posters will also be available for viewing throughout the conference. It is expected that approximately 450 medical professionals and researchers will attend the Scientific Sessions. This application is seeking funds to support only the Scientific Sessions. PUBLIC HEALTH RELEVANCE: The Scientific Sessions will be addressing new pathogenetic mechanisms and treatment as it possibly relates to PAH. The number of PAH patients in the United States is not known, but it is estimated that 20,000-30,000 patients (Rino Aldrighetti, personal communication) are receiving treatment for the disease. There are now eight FDA approved treatments for PAH and patients are living longer, but their quality of life is often poor. There is no cure for PAH and survival is variable, ranging from months to more than 20 years. This meeting will be an attempt to identify mechanisms in the inflammatory and growth factor pathways that may have the potential to serve as targets for future treatments for PAH. It will bring together PAH scientists and clinicians with other cardiovascular scientists to exchange information on common research interests. It should also serve to foster collaboration between basic scientists and clinicians to stimulate more translational research.

描述（由申请人提供）： 肺动脉高压协会（PHA）成立于1990年，当时约有100名会员，目前已发展到10，000名会员，其中包括患者，护理人员，临床医生，研究科学家和专职医疗人员。它支持广泛的服务和教育和研究计划，使其庞大而多样化的成员受益。PHA支持的主要活动之一是两年一度的国际肺动脉高压会议。这次会议的独特之处在于它将医疗专业人员和研究人员与患者聚集在一起。第九届国际会议将于2010年6月24-27日在加州的加登格罗夫举行。会议将从为研究人员和卫生专业人员举办的题为“肺动脉高压（PAH）中的炎症和生长因子”的科学会议开始开始。科学会议于6月24日晚上开始，并于6月25日全天持续。科学会议的具体目标是：1）提供一个论坛，介绍PAH相关主题的关键研究成果; 2）鼓励就PAH合作研究的新方向公开交流想法; 3）突出该领域初级研究人员的研究成就，以促进对PAH的终身承诺;（4）促进基础与临床研究人员的合作，促进更多的转化研究。科学会议将包括讨论心血管医学研究和教育基金（CMREF）计划的开幕会议和NHLBI肺血管SCCOR计划的更新，全天会议，五位主题科学家讨论炎症，生长因子和心肺疾病的各个方面，海报会议的四个摘要演示，以及预期75张海报的海报观看会议。这些海报也将在整个会议期间提供供观看。预计约有450名医学专业人员和研究人员将参加科学会议。该申请正在寻求资金，以支持只有科学会议。 公共卫生相关性： 科学会议将讨论新的发病机制和治疗，因为它可能与PAH有关。美国PAH患者的数量尚不清楚，但据估计有20，000 - 30，000名患者（Rino Aldrighetti，个人交流）正在接受该疾病的治疗。现在有八种FDA批准的PAH治疗方法，患者的寿命更长，但他们的生活质量往往很差。PAH无法治愈，生存期不定，从几个月到20年以上不等。本次会议将试图确定炎症和生长因子途径中的机制，这些机制可能成为未来PAH治疗的目标。它将汇集多环芳烃科学家和临床医生与其他心血管科学家，交流共同研究兴趣的信息。它还应有助于促进基础科学家和临床医生之间的合作，以刺激更多的转化研究。